Dermatomyositis as a presentation of neuromyelitis optica spectrum disorder
- 1 January 2015
- journal article
- case report
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 278, 108-111
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Most Patients With Cancer‐Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP‐2 or Transcription Intermediary Factor 1γArthritis & Rheumatism, 2013
- Interstitial Lung Disease in Myositis: Clinical Subsets, Biomarkers, and TreatmentCurrent Rheumatology Reports, 2012
- Ifih1 Gene Dose Effect Reveals MDA5-Mediated Chronic Type I IFN Gene Signature, Viral Resistance, and Accelerated AutoimmunityThe Journal of Immunology, 2012
- Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patientsJournal of Neuroinflammation, 2012
- Malignancy and myositis: novel autoantibodies and new insightsCurrent Opinion in Rheumatology, 2010
- Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositisBMC Musculoskeletal Disorders, 2010
- Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosusJournal of Cutaneous Pathology, 2008
- Cancer and myositis: new insights into an old associationCurrent Opinion in Rheumatology, 2006
- Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositisRheumatology, 2006
- An open label study of the effects of rituximab in neuromyelitis opticaNeurology, 2005